KORU Medical Systems Inc

KORU Medical Systems Inc(KRMD)の株式分析

$3.030

-0.222 (-7.34%)終値時点

Loading chart…
高値
3.310
始値
3.310
出来高加重平均価格
3.09
出来高
143.77K
時価総額
130.43M
安値
2.920
売買代金
443.78K
EV/EBITDA(TTM)
36.88

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

www.korumedical.com

AI分析 of KORU Medical Systems Inc (KRMD)

買い

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

バリュエーション指標

KORU Medical Systems Inc(KRMD)の現在の予想PERは76.34で、5年平均は-7.42です。

予想PER

適正
5年平均 P/E
-7.42
現在のP/E
76.34
割高
108.26
割安
-123.09

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-24.07
現在のEV/EBITDA
36.88
割高
59.60
割安
-107.75

予想PSR

割安
5年平均 P/S
4.07
現在のP/S
2.53
割高
5.09
割安
3.05

Alphio AI による KRMD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%KRMD

$3.23

シナリオ価格

基

基本

基本 · 50%KRMD

$2.98

シナリオ価格

弱

弱気

弱気 · 25%KRMD

$2.84

シナリオ価格

KRMD を保有するクジラ

F

First Light Asset Management, LLC

+ を保有KRMD

+0.00%

3か月リターン

イベントタイムライン

2026-08-05 (ET)

17:30:00

Company Reiterates Positive EBITDA Outlook for FY26

17:30:00

Koru Reports Q2 Revenue of $12.0M, Exceeding Expectations

2026-05-06 (ET)

16:20:00

Koru Medical Affirms FY26 Revenue View of $47.5M-$50M

16:20:00

Koru Medical Reports Q1 Revenue of $11.77M

2026-03-12 (ET)

16:40:00

KORU Medical Reports Q4 Revenue of $10.9M

ニュース

KRMD のよくある質問 — Alphio AI が回答

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める